C1QA Gene — Complement Component 1q A Chain

📖 Wiki Page

gene2340 wordssynced 2026-04-02

C1QA Gene — Complement Component 1q A Chain

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">c1q</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>C1Q</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>c1q</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=C1Q" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/ali" style="color:#ef9a9a">ALI</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1048 edges</a></td>
</tr>
</table>

Introduction

C1QA encodes the A-chain of complement component C1q, a core initiator of the classical complement pathway and a major regulator of immune signaling in the central nervous system (CNS). In the healthy brain, C1q participates in developmental synaptic refinement and immune surveillance. In aging and neurodegeneration, C1q expression rises strongly in vulnerable regions and is linked to maladaptive synapse elimination, microglial activation, and circuit dysfunction. [@stevens2007] [@hong2016] [@litvinchuk2018]

...

C1QA Gene — Complement Component 1q A Chain

Introduction

C1q is produced by CNS myeloid-lineage cells (especially [Microglia](/cell-types/microglia)) and, in disease contexts, can localize to synapses, dystrophic neurites, extracellular protein aggregates, and vascular interfaces. These features make C1QA a high-value node connecting innate immunity, synaptic biology, and disease progression in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), and related disorders. [@hong2016] [@liddelow2017] [@depboylu2011]

Overview

C1QA encodes the A-chain of complement component C1q, a pattern-recognition molecule that serves as the initiating complex of the classical complement cascade. The C1q complex consists of six heterotrimeric subunits (three A, three B, three C chains) that assemble into a characteristic "bouquet of tulips" structure, with globular heads that recognize diverse molecular targets and collagen-like tails that engage downstream C1r and C1s serine proteases. [@stevens2007]

In the nervous system, C1q performs dual roles: during development, it participates in activity-dependent synaptic refinement through complement-mediated microglial phagocytosis; in the adult and aging brain, it maintains immune surveillance functions. However, dysregulated C1q expression in neurodegenerative conditions triggers pathological synapse loss, neuroinflammation, and exacerbates protein pathology propagation. [@wu2019] [@czirr2017]

Gene And Protein Context

Symbol: C1QA
Full name: Complement C1q A chain
Chromosomal locus: 1p36.12
NCBI Gene: [712](https://www.ncbi.nlm.nih.gov/gene/712)
Ensembl: [ENSG00000173372](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000173372)
UniProt (protein subunit): [P02745](https://www.uniprot.org/uniprotkb/P02745/entry)
Protein molecular weight: ~26 kDa (A chain), assembled complex ~410 kDa
Expression: Primarily expressed in myeloid cells (monocytes, macrophages, microglia); astrocytic expression detected in disease states

The mature C1q complex is assembled from C1QA, C1QB, and C1QC subunits into a bouquet-like pattern-recognition molecule. Each chain contributes to collagen-like domains and globular heads that bind immune targets and altered host surfaces. In brain tissue, this structure allows C1q to bind synaptic elements and trigger downstream complement activity through [C3 Protein](/proteins/c3-protein) and complement receptors. [@stevens2007] [@hong2016]

Molecular Mechanisms In The Nervous System

Complement Cascade Initiation

C1q functions as the recognition component of the C1 complex (C1qr2s2). Upon binding to pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), or altered self-surfaces including aggregated proteins and synaptic membranes, C1q undergoes conformational changes that activate the associated C1r and C1s serine proteases. This triggers the classical complement cascade, leading to C4b/C2b cleavage and formation of the C3 convertase (C4b2a), which then generates downstream effectors including C3a and C3b opsonins. [@gerakis2020]

In the CNS, C1q can be activated by multiple triggers relevant to neurodegeneration: amyloid-beta plaques, hyperphosphorylated tau aggregates, alpha-synuclein fibrils, and complement-opsonized synapses. The resulting complement activation creates a self-amplifying loop where early synaptic tagging by C1q leads to C3-mediated microglial phagocytosis. [@schartz2020]

Synaptic Pruning: Development vs. Disease

During postnatal brain development, C1q marks surplus synapses for elimination in an activity-dependent manner. Synaptic activity modulates the complement tagging system: more active synapses are protected through unknown mechanisms while less active synapses become tagged with C1q and subsequently eliminated by microglia via complement receptor 3 (CR3/CD11b/CD18). This developmental pruning refines neural circuits and establishes appropriate connectivity. [@stevens2007]

In neurodegenerative disease, this developmental program appears to be reactivated pathologically. Multiple mechanisms contribute to inappropriate C1q-mediated synapse loss:

Age-related C1q increase: C1q protein levels in brain tissue increase dramatically with normal aging, particularly in hippocampus and cortex. This age-related "priming" lowers the threshold for pathological synapse elimination. [@stephan2013]

Disease-specific triggers: Amyloid-beta, tau, and alpha-synuclein aggregates can directly or indirectly activate the classical complement pathway, leading to excessive C1q deposition on synapses. [@czirr2017]

Microglial activation: Primed or disease-associated microglia exhibit enhanced complement production and respond more aggressively to C1q-opsonized targets. [@liddelow2017]

Astrocytic C1q: Emerging evidence shows astrocytes can produce C1q in response to inflammatory signals, potentially contributing to synaptic loss through non-microglial mechanisms. [@chen2024]

Interaction With Pattern Recognition Receptors

C1q interacts with multiple pattern recognition receptors beyond the classical complement pathway. Notably, C1q can engage Toll-like receptor 4 (TLR4) on microglia, triggering NF-κB-dependent inflammatory cytokine production. This TLR4-C1q interaction provides a molecular link between complement activation and the broader neuroinflammatory response in Parkinson's disease and potentially other neurodegenerative conditions. [@wu2019]

Physiologic Function In The Nervous System

Complement initiation and immune surveillance

C1q recognizes molecular patterns and initiates classical complement signaling. In CNS tissue, this can support debris clearance and immune homeostasis under tightly constrained conditions. The complement system provides a first line of defense against pathogens and facilitates clearance of apoptotic cells and protein aggregates. [@stevens2007] [@dejanovic2018]

During development, C1q tags subsets of synapses for microglial pruning. This process helps optimize connectivity but becomes pathologic when re-engaged in aged or diseased brain circuits. The balance between protective and pathological C1q function depends on context, with developmental pruning being highly regulated whereas disease-associated pruning becomes dysregulated. [@stevens2007] [@hong2016]

Glial crosstalk

C1q is also part of a [microglia](/cell-types/microglia-neuroinflammation)-astrocyte signaling axis: activated microglia can release C1q alongside cytokine mediators that drive reactive astrocyte programs. This links complement activity to broader neuroinflammatory states and secondary neuronal stress. The microglial-astrocyte crosstalk mediated by C1q and related complement components contributes to the emergence of neurotoxic reactive astrocytes. [@liddelow2017]

Vascular interface functions

C1q localizes to cerebral vasculature and may participate in blood-brain barrier maintenance and vascular clearance pathways. In disease states, C1q deposition at the neurovascular unit could contribute to vascular dysfunction and impaired clearance of toxic proteins. [@zabel2019]

Role In Neurodegeneration

Alzheimer's disease

Multiple lines of evidence connect C1q to early synaptic injury in AD models. Complement-dependent synapse loss can occur before large-scale neuronal death and correlates with cognitive decline. C1q engagement with [Microglial Synaptic Pruning Dysregulation in Neurodegeneration](/mechanisms/microglial-synaptic-pruning-dysregulation) and [Complement-Mediated Synapse Loss](/mechanisms/complement-mediated-synapse-loss) is now a central mechanistic framework. [@hong2016] [@litvinchuk2018] [@dejanovic2018]

The temporal sequence of events in AD models suggests that soluble oligomeric amyloid-beta (the most synaptotoxic species) induces C1q expression and synapse tagging before plaques become extensive. This C1q-dependent mechanism may explain why synapse loss precedes neuronal loss in AD and why cognitive deficits appear early in disease progression. [@koffie2012] [@carroll2020]

Importantly, C1q appears to synergize with other AD-related mechanisms. Tau pathology propagates via complement-dependent mechanisms, and C1q antibodies can rescue tau-induced synapse loss in model systems. This suggests a potential therapeutic approach targeting complement to preserve synapses across multiple pathological substrates. [@dejanovic2018]

Tauopathies and other dementias

Human tauopathy datasets report complement dysregulation with C1q/C3 pathway involvement, reinforcing the idea that complement activation is not restricted to amyloid-dominant settings. Studies in Alzheimer's disease, progressive supranuclear palsy, corticobasal degeneration, and primary tauopathies all show evidence of complement activation that correlates with disease severity. [@vidalpineiro2024]

The relationship between tau pathology and complement appears bidirectional: tau pathology activates complement, and complement activation may in turn accelerate tau propagation through microglial-mediated mechanisms. This creates a feed-forward loop that could explain the stereotypical progression of tau pathology in the aging brain. [@litvinchuk2018]

Parkinsonian syndromes

Pathologic studies in PD substantia nigra describe C1q involvement in neuromelanin-associated immune responses. Although disease effects likely vary by region and stage, complement signaling remains a plausible contributor to chronic microglial activation in nigrostriatal degeneration. The interaction between neuromelanin release from dying neurons and complement activation provides a mechanism for chronic neuroinflammation in PD. [@depboylu2011]

Additionally, C1q interactions with TLR4 on microglia induce pro-inflammatory responses that could contribute to dopaminergic neuron vulnerability. The convergence of complement and pattern recognition receptor signaling provides a molecular framework for understanding how protein aggregates trigger neuroinflammation across synucleinopathies. [@wu2019]

Amyotrophic lateral sclerosis (ALS)

Complement activation, including C1q deposition, has been documented in ALS models and human tissue. Given the prominence of synaptic dysfunction in ALS and the role of complement in synapse elimination, C1q-mediated mechanisms may contribute to early synaptic pathology in motor neuron disease. However, this area remains less characterized than AD and PD.

Disease Associations And Translational Relevance

AD risk biology

C1q-dependent synaptic pruning is increasingly viewed as an upstream driver of network failure rather than only a late epiphenomenon. The demonstration that C1q blockade preserves synapses and improves cognitive outcomes in multiple AD models has solidified this perspective. Therapeutic targeting of C1q represents a strategy to intervene in disease progression before irreversible neuronal loss occurs. [@hong2016] [@litvinchuk2018]

Aging vulnerability

Marked age-related C1q accumulation may lower the threshold for complement overactivation after proteotoxic or vascular stress. This "inflammaging" effect on complement systems could explain why neurodegenerative diseases predominantly affect older adults. Interventions that normalize C1q levels or function might therefore have particular utility in the aging population. [@stephan2013]

Therapeutic strategy

Targeting early complement nodes (C1q/C3 axis) is under active translational investigation to preserve synapses while avoiding broad immunosuppression. Multiple approaches are being explored:

Anti-C1q antibodies: Monoclonal antibodies that block C1q function have shown efficacy in preclinical models. These agents could prevent pathological synapse tagging while sparing beneficial developmental pruning. [@carroll2020] [@shi2024]

Small molecule inhibitors: Small molecules that block C1q-target interactions or prevent C1 complex assembly represent an alternative approach with potentially different pharmacokinetic properties. [@schneider2022]

CR3/CD11b modulation: Since microglia mediate synapse elimination through CR3, modulating this receptor provides another potential intervention point. [@czirr2017]

Astrocyte-targeted approaches: Given the emerging role of astrocytic C1q production, targeting astrocyte-specific complement expression could provide more targeted effects. [@chen2024]

Non-human primate studies have demonstrated that C1q inhibition can prevent age-related synaptic loss, supporting the translational relevance of this approach. [@sink2023]

Biomarker linkage

C1q biology intersects with inflammatory and glial biomarker programs (for example [sTREM2 (Soluble TREM2) - Microglial Biomarker](/biomarkers/strem2)). Measurement of C1q levels in cerebrospinal fluid and plasma could provide insights into complement activation status in patients, potentially serving as a biomarker for disease stage or treatment response. Additionally, genetic variants in complement genes may influence AD risk, though the relationship remains complex. [@vidalpineiro2024]

Experimental Models And Methods

Common approaches used to study C1QA in neurodegeneration include:

Genetic perturbation: C1qa knockout or complement-pathway manipulation in mouse models for causal testing of synapse loss and behavioral outcomes. Knockout mice are protected from synapse loss in multiple models, providing strong evidence for C1q's pathological role. [@stevens2007] [@hong2016]

Histology and spatial mapping: region-resolved quantification of C1q deposition on synaptic markers, neurites, and glial compartments. Techniques include confocal microscopy, array tomography, and spatial transcriptomics. [@litvinchuk2018] [@stephan2013]

Single-cell and transcriptomic analyses: mapping C1QA-enriched glial states and coupling them to progression-stage phenotypes. Single-cell RNA sequencing has identified C1q-expressing microglial clusters associated with neurodegeneration. [@vidalpineiro2024]

Interventional pharmacology: pathway-level inhibition of complement signaling in preclinical paradigms to test rescue of synaptic and cognitive endpoints. Antibody blockade, genetic knockouts, and small molecule inhibitors have all been tested. [@dejanovic2018]

Human tissue studies: Postmortem brain tissue analysis from AD, PD, and other neurodegenerative disease patients to validate findings from model systems. Human studies confirm increased C1q expression and deposition in disease states. [@vidalpineiro2024]

iPSC models: Human-induced pluripotent stem cell-derived neurons and microglia allow study of C1q effects in human cells, potentially identifying species-specific mechanisms. [@yang2023]

Clinical Trials And Therapeutic Development

While no C1q-targeted therapies have reached late-stage clinical trials for neurodegenerative diseases as of 2024, several programs are in development:

Anti-C1q antibodies have completed preclinical development and may enter clinical trials for AD
Complement inhibitors from other indications (e.g., eculizumab for atypical hemolytic uremic syndrome) have been repurposed in pilot studies for neurological conditions
Gene therapy approaches to modulate complement expression are under investigation

The field awaits translation of the strong preclinical evidence for C1q as a therapeutic target into clinical benefit. Key questions remain about the optimal timing of intervention, patient selection, and safety of long-term complement inhibition.

Research Gaps And Future Directions

Temporal dynamics: When does C1q-mediated synapse loss become irreversible? What determines the transition from protective to pathological complement activation?

Cell-type specificity: What determines whether C1q acts protectively (debris clearance) vs. pathologically (synapse elimination)? Can we target pathological C1q while sparing beneficial functions?

Biomarkers: Development of validated C1q-related biomarkers for patient stratification and treatment monitoring

Combination therapies: How should C1q-targeted approaches be combined with other therapeutic strategies (anti-amyloid, anti-tau, neuroprotection)?

Species translation: How well do findings from mouse models translate to human disease? What role do species differences play?

References

[Stevens et al., The classical complement cascade mediates CNS synapse elimination (2007)](https://pubmed.ncbi.nlm.nih.gov/18083105/)

[Hong et al., Complement and microglia mediate early synapse loss in Alzheimer mouse models (2016)](https://pubmed.ncbi.nlm.nih.gov/27033548/)

[Litvinchuk et al., Complement C3aR inactivation attenuates tau pathology (2018)](https://pubmed.ncbi.nlm.nih.gov/30415998/)

[Liddelow et al., Neurotoxic reactive astrocytes are induced by activated microglia (2017)](https://pubmed.ncbi.nlm.nih.gov/28099414/)

[Depboylu et al., C1q in the clearance of extracellular neuromelanin in PD (2011)](https://pubmed.ncbi.nlm.nih.gov/21343881/)

[Dejanovic et al., Changes in the synaptic proteome in tauopathy and rescue by C1q antibodies (2018)](https://pubmed.ncbi.nlm.nih.gov/30392797/)

[Vidal-Pineiro et al., Complement dysregulation in human tauopathies (2024)](https://pubmed.ncbi.nlm.nih.gov/40420510/)

[Stephan et al., A dramatic increase of C1q protein in the CNS during normal aging (2013)](https://pubmed.ncbi.nlm.nih.gov/23946404/)

[Wu et al., C1q interacts with TLR4 to induce neuroinflammation in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31733751/)

[Czirr et al., Microglial complement receptor 3 regulates brain Aβ and tau pathology (2017)](https://pubmed.ncbi.nlm.nih.gov/29282216/)

[Gerakis & Hetz, C1q as a therapeutic target in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32989261/)

[Schartz et al., Blocking complement reduces post-injury synaptic loss (2020)](https://pubmed.ncbi.nlm.nih.gov/32470174/)

[Carroll et al., C1q antibody injection reduces synapse loss in AD model (2020)](https://pubmed.ncbi.nlm.nih.gov/33287885/)

[Zabel et al., Microglial activation and amyloid deposition in aging and AD (2019)](https://pubmed.ncbi.nlm.nih.gov/29877656/)

[Koffie et al., Alzheimer's disease: synapses gone cold (2012)](https://pubmed.ncbi.nlm.nih.gov/22314447/)

[Schneider et al., C1q-targeted therapeutics in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35644609/)

[Yang et al., C1q/TNF-related proteins in neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37866089/)

[Sink et al., C1q inhibition prevents age-related synaptic loss in non-human primates (2023)](https://pubmed.ncbi.nlm.nih.gov/38517823/)

[Chen et al., Astrocytic C1q contributes to neurotoxicity in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38489334/)

[Shi et al., C1q blockade reduces microglial activation in 5xFAD mice (2024)](https://pubmed.ncbi.nlm.nih.gov/38723289/)

Pathway Diagram

The following diagram shows key molecular relationships for c1q based on knowledge graph edges:

Mermaid diagram (expand to render)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[SASP-Mediated Complement Cascade Amplification](/hypothesis/h-58e4635a) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: C1Q/C3

Pathway Diagram

The following diagram shows the key molecular relationships involving C1QA Gene — Complement Component 1q A Chain discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

C1QA Gene — Complement Component 1q A Chain

C1QA Gene — Complement Component 1q A Chain

Introduction

C1QA Gene — Complement Component 1q A Chain

Introduction

Overview

Gene And Protein Context

Molecular Mechanisms In The Nervous System

Complement Cascade Initiation

Synaptic Pruning: Development vs. Disease

Interaction With Pattern Recognition Receptors

Physiologic Function In The Nervous System

Complement initiation and immune surveillance

Synapse refinement

Glial crosstalk

Vascular interface functions

Role In Neurodegeneration

Alzheimer's disease

Tauopathies and other dementias

Parkinsonian syndromes

Amyotrophic lateral sclerosis (ALS)

Disease Associations And Translational Relevance

AD risk biology

Aging vulnerability

Therapeutic strategy

Biomarker linkage

Experimental Models And Methods

Clinical Trials And Therapeutic Development

Research Gaps And Future Directions

See Also

References

Pathway Diagram

Pathway Diagram

C1QA Gene — Complement Component 1q A Chain

C1QA Gene — Complement Component 1q A Chain

Introduction

C1QA Gene — Complement Component 1q A Chain

Introduction

Overview

Gene And Protein Context

Molecular Mechanisms In The Nervous System

Complement Cascade Initiation

Synaptic Pruning: Development vs. Disease

Interaction With Pattern Recognition Receptors

Physiologic Function In The Nervous System

Complement initiation and immune surveillance

Synapse refinement

Glial crosstalk

Vascular interface functions

Role In Neurodegeneration

Alzheimer's disease

Tauopathies and other dementias

Parkinsonian syndromes

Amyotrophic lateral sclerosis (ALS)

Disease Associations And Translational Relevance

AD risk biology

Aging vulnerability

Therapeutic strategy

Biomarker linkage

Experimental Models And Methods

Clinical Trials And Therapeutic Development

Research Gaps And Future Directions

See Also

References

Pathway Diagram

Related Hypotheses

Pathway Diagram